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Background: Ephrin-B2 is the sole physiologically-relevant ligand of the receptor tyrosine kinase
EphB4, which is over-expressed in many epithelial cancers, including 66% of prostate cancers, and
contributes to cancer cell survival, invasion and migration. Crucially, however, the cancer-
promoting EphB4 signalling pathways are independent of interaction with its ligand ephrin-B2,
as activation of ligand-dependent signalling causes tumour suppression. Ephrin-B2, however, is
often found on the surface of endothelial cells of the tumour vasculature, where it can regulate
angiogenesis to support tumour growth. Proteolytic cleavage of endothelial cell ephrin-B2 has
previously been suggested as one mechanism whereby the interaction between tumour cell-
expressed EphB4 and endothelial cell ephrin-B2 is regulated to support both cancer promotion
and angiogenesis.
Methods: An in silico approach was used to search accessible surfaces of 3D protein models for
cleavage sites for the key prostate cancer serine protease, KLK4, and this identiﬁed murine
ephrin-B2 as a potential KLK4 substrate. Mouse ephrin-B2 was then conﬁrmed as a KLK4
substrate by in vitro incubation of recombinant mouse ephrin-B2 with active recombinant human
KLK4. Cleavage products were visualised by SDS-PAGE, silver staining and Western blot and
conﬁrmed by N-terminal sequencing.
Results: At low molar ratios, KLK4 cleaved murine ephrin-B2 but other prostate-speciﬁc KLK family
members (KLK2 and KLK3/PSA) were less efﬁcient, suggesting cleavage was KLK4-selective. The
primary KLK4 cleavage site in murine ephrin-B2 was veriﬁed and shown to correspond to one of the
in silico predicted sites between extracellular domain residues arginine 178 and asparagine 179.
Surprisingly, the highly homologous human ephrin-B2 was poorly cleaved by KLK4 at these low
molar ratios, likely due to the 3 amino acid differences at this primary cleavage site.lsevier Inc. This is an open access article under the CC BY-NC-ND license
4.0/).
eptor tyrosine kinase; KLK4, kallikrein related peptidase 4; eB2, ephrin-B2; MMP, matrix
metalloproteases; BPH, benign prostatic hyperplasia; PSA, prostate speciﬁc antigen; ePICS,
e sites; kDa, kiloDalton
Biomedical Innovation at the Translational Research Institute, 37 Kent St, Woolloongabba 4102,
.-A. Stephenson).
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 3 ( 2 0 1 5 ) 1 3 6 – 1 4 6 137Conclusion: These data suggest that in in vivo mouse xenograft models, endogenous mouse ephrin-
B2, but not human tumour ephrin-B2, may be a downstream target of cancer cell secreted human
KLK4. This is a critical consideration when interpreting data from murine explants of human
EphB4þ/KLK4þ cancer cells, such as prostate cancer cells, where differential effects may be seen in
mouse models as opposed to human clinical situations.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
EphB4 is a member of the large Eph family of type 1 transmem-
brane receptor tyrosine kinases (RTKs) [1,2], but unlike other Eph
family members has only a single physiologically relevant ligand,
ephrin-B2 [3]. In a mechanism exclusive to the Eph family, Eph
receptors expressed on the plasma membrane of epithelial cells
interact with their ephrin ligands which are also membrane-
anchored on a neighbouring cell, commonly an endothelial cell, to
activate bidirectional signalling pathways—forward into the Eph
receptor expressing cell and reverse into the ligand expressing
cell [2]. EphB4 and ephrin-B2 are both critical in development and
for the formation of the cardiovascular system and are particu-
larly important in demarcating arterial (ephrin-B2) from venous
(EphB4) endothelial cells which is critical for formation of the
capillary plexus [4–7].
The expression of several Eph receptors is signiﬁcantly dysre-
gulated in cancer and EphB4 in particular is commonly over-
expressed in many epithelial cancers, including 66% of prostate
cancers (PCa) [8,9]. Knockdown experiments using PCa cell lines
have shown that EphB4 is a key regulator of PCa cell survival,
invasion and migration [8]. Recent in vitro studies indicate that
these cancer-promoting EphB4 signalling pathways are mostly
independent of ephrin-B2 interaction, as addition of excess
clustered soluble ephrin-B2 ectodomain to cancer cells over-
expressing EphB4 activates/phosphorylates the EphB4 kinase
domain and can cause growth suppression in vitro [10–12].
However, ephrin-B2 is also present in tumours, expressed pri-
marily on the endothelial cells of the tumour vasculature and by
ﬁbroblasts in the surrounding prostate tumour stroma [13,14].
Several groups have shown that endothelial cell ephrin-B2 plays a
key role in regulating angiogenesis and lymphangiogenesis, an
important element in supporting tumour growth and for arresting
cells during site-speciﬁc metastatic dissemination [15–17]. Thus,
collectively these studies suggest a ﬁne balance and tight regula-
tion of EphB4-ephrin-B2 interaction exists that is critical to the
promotion or suppression of tumour growth and spread.
Recent evidence has shown that this balance can be altered
through cleavage of the ectodomain of ephrin-B2 by metalloprotei-
nases (MMPs), γ-secretase and A Disintegrin and Metalloproteases
(ADAMs) 8, 10 and 13 [18–22]. This results in activation of ephrin-B2
and Src signalling pathways and upregulation of its angiogenic
properties [20]. Other ephrin proteins have also been shown to be
susceptible to protease cleavage [18,23–27]. We therefore hypothe-
sised that ephrin-B2 may be susceptible to proteolytic cleavage by
proteases that are relevant in PCa.
The serine protease kallikrein-related peptidase 4 (KLK4) is
over-expressed and secreted from PCa cells and plays an increas-
ingly recognised key role in PCa cell biology, cleaving a numberof known tumour modulators and extracellular matrix proteins
[28–33]. Increased expression of KLK4 in 60 PCa patient samples
when compared with 59 benign prostatic hyperplasia (BPH)
samples positively correlated with PCa stage and pre-operative
PSA serum concentration [28]. Accordingly, when compared with
normal prostate epithelia KLK4 protein was over-expressed in
malignant prostate and predominantly in the nucleus of basal
cells [29]. KLK4 over-expression has been linked to increases in
proliferation, migration and epithelial to mesenchymal transition
although this may be cell context dependent [29–30]. More
recently, Seiz et al. developed two KLK4-speciﬁc antibodies for
an immunohistochemical study of PCa samples and reported that
KLK4 is upregulated in cancerous glandular epithelial cells from
early-stage but not late-stage PCas [31]. Although the full biolo-
gical contribution of KLK4 to PCa is not known, Wang et al. have
described an interesting feedback mechanism where KLK4
released from PCa cells activates PAR-1 expressed by surrounding
stromal cells and this, in turn, releases cytokines (IL-6) that
stimulate cancer cell proliferation and increased production of
KLK4 [32].
Using an in silico approach, 3D protein models in the UniProt
database were searched for protein crystal structures which
presented potential KLK4 consensus cleavage sites on their
surfaces, sites which are therefore accessible to the protease.
Mouse ephrin-B2 was one of the proteins for which potential
KLK4 cleavage sites were identiﬁed. Here we report biochemical
validation of the in silico prediction and show that KLK4 is able to
speciﬁcally cleave murine ephrin-B2. However, surprisingly it has
a much reduced efﬁcacy in cleaving human ephrin-B2. This is an
important distinction and has potentially major implications for
the interpretation of data from murine explants of human
EphB4þ/KLK4þ cancer cells where differential effects may be
seen in mouse models as opposed to human clinical situations.Materials and methods
Recombinant proteins and antibodies
Recombinant auto-activating KLK4 was prepared in-house using
Splicing by Overlap Extension PCR to couple the coding sequence
of mature KLK4 to the pro-domain of prostate speciﬁc antigen
(PSA/KLK3) (at the 50 end) and V5 and poly-histidine encoding
sequences at the 30 end in the pIB plasmid [34]. Recombinant
KLK4 is produced as an inactive zymogen, but has the capacity to
self-cleave and remove the PSA pro-domain and this results in
release of an auto-activated form of the KLK4 enzyme. The KLK4-
pIB plasmid was used to transfect cells of the insect cell line Sf9
using a previously described method [35]. Production of
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Fig. 1 – Identiﬁcation of ephrin-B2 as a potential substrate of
KLK4. (A) Model of ephrin-B2 within the plasma membrane
showing the crystal structure of the extracellular Eph receptor
binding domain (PBD 2HLE) (blue), a single transmembrane
helix (red) and the unresolved intracellular domain (dark red)
that includes a PDZ domain at the C-terminal end (dark blue).
(B) An in silico approach (enhanced Proteomic Identiﬁcation of
Cleavage Sites (ePICS)—Stansﬁeld, Stephens, Clements;
manuscript in preparation) was used to identify potential
KLK4 consensus cleavage sites in proteins for which crystal
structures were available. High ePICS scores (44, red boxes)
identify murine ephrin-B2 as a potential target for KLK4
cleavage. Cleavage sites are within the extracellular domain of
the protein (UniPROT Annotations—top green bar). The yellow
UniPROT modiﬁcations bar identiﬁes the positions of amino
acids that may be glycosylated (red spot tags) and
phosphorylated (yellow spot tags) and disulﬁde bridges (black
brackets). (C) ePICS scores also suggest KLK4 may cleave
human ephrin-B2.
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antichymotrypsin, an inhibitor of KLK4, using 100 μM D-Val-Leu-
Arg 7-Amindo-4-triﬂuoromethylcoumarin (Sigma-Aldrich Cor-
poration, NSW, Australia) as the substrate in 100 μl assay buffer
(50 mM Tris, 50 mM NaCl, pH 8.8, 0.01% Tween-20) [36]. Kallik-
reins KLK2 and KLK3/PSA, produced in a similar manner, were
already available in the laboratory. Recombinant murine ephrin-
B2-Fc and recombinant human ephrin-B2-Fc were purchased
from R&D Systems (Minneapolis, Minnesota, USA). The less-
selective serine proteases trypsin (Sigma), chymotrypsin (Sigma)
and GluC (New England Biolabs, Ipswich, Massachusetts, USA),
and the subtilisin-like proprotein convertase Furin (New England
Biolabs) were used as positive (trypsin, chymotrypsin and GluC)
and negative controls (Furin) for cleavage. Two ephrin-B2 poly-
clonal antibodies raised against distinct extracellular domain
epitopes were purchased from Santa Cruz Biotechnology (Santa
Cruz, California, USA)—the rabbit anti-ephrin-B2 (P-20) raised
against a common (but not disclosed) human/mouse extracellular
domain epitope and the rabbit anti-ephrin-B2 (H-83) raised
against the human/mouse sequence, amino acids 168–235.
Ephrin-B2-Fc digestion with KLK4 and other proteases
Recombinant murine ephrin-B2-Fc protein was diluted and incu-
bated overnight at 37 1C with the proteases KLK4, the closely related
kallikreins KLK2 or KLK3/PSA, the less-selective serine proteases
trypsin, chymotrypsin and GluC, or the subtilisin-like proprotein
convertase Furin. Incubations were either in the supplier’s recom-
mended 1 reaction buffer or phosphate-buffered saline. KLK4
reactions were performed in a reaction buffer containing 50 mM
Tris–HCl and 50 mM NaCl, pH 8.5. To ﬁnd the optimum molar ratio
for ephrin-B2 cleavage, the KLK4 digestion experiment was per-
formed with a ﬁxed amount of ephrin-B2 and decreasing amounts
of active KLK4 from a 1:1 ephrin-B2 to KLK4 molar ratio (100 ng
ephrin-B2þ41 ng KLK4) to a 1:1/1000 ephrin-B2 to KLK4 ratio
(100 ng ephrin-B2þ41 pg KLK4). For the other proteases, reactions
contained 100 ng of ephrin-B2 and 1 ng of the protease in either the
supplied buffer or in PBS. The reactions were terminated by adding
SDS-loading buffer (0.01 M Trizma, 40% Glycerol, 4% SDS, 0.006%
Bromophenol Blue, 5% β-mercaptoethanol, pH 6.8) and boiled at
95 1C for 5 min to denature the proteins. Samples were electro-
phoresed into 10% separating SDS-PAGE gels through a 4% stacking
gel and individual proteins visualized by silver staining or Western
blotting. De-glycosylation was performed using PNGase F following
the manufacturer's instructions (New England Biolabs). KLK4 activity
in the PNGase F reaction buffer was conﬁrmed.
Western blot analysis
Separated proteins were transferred by electroblotting onto
BioTrace™ NT nitrocellulose membrane (Pall, Pensacola, Florida,
USA). The membranes were blocked with Western blocking
reagent (Roche, Indianapolis, Indiana, USA) before incubation
with the primary antibodies—rabbit anti-mouse ephrin-B2 (P-
20; 1:1000) or rabbit anti-mouse ephrin-B2 (H-83; 1:500) fol-
lowed by peroxidase-conjugated goat anti-mouse secondary
antibodies (Pierce, from Thermo Fisher Scientiﬁc, Scoresby VIC,
Australia) (used at a 1:30,000 dilution). Immunoreactivity was
detected using the Amersham™ ECL Plus Chemiluminescence kit
(GE Healthcare, Rydalmere, NSW, Australia).Silver staining
After electrophoresis, gels were ﬁxed in 40% methanol/10% acetic
acid for at least 30 min and rinsed brieﬂy before addition of K3Fe
(CN)6/Na2S2O3(5H2O) solution for 5 min. After rinsing, 12 mM
AgNO3 was added for 20 min and the gel washed brieﬂy before
the protein bands were developed using formaldehyde/2.9%
1 2 34 5
Mouse ephrin-B2–PBD 1IKO Human ephrin-B2–PBD  3GXU 
Fig. 2 – Position of predicted KLK4 cleavage sites within the sequence and the folded protein. (A) Amino acid sequence alignment
of partial extracellular domains of the human ephrin-B2 (Human) and mouse ephrin-B2 (Mouse) proteins. The sequences of the
extracellular domains are shown in black, the transmembrane sequence is green and the intracellular portion is blue. Amino acids
showing identity between the two sequences are indicated by the asterisk (*) below the alignment, a colon (:) indicates the amino
acids are conserved, a full stop (.) indicates a semi-conserved substitution and a blank space indicates amino acids that are non-
conserved. An error in the PBD entry 2HLE (used for modelling in Fig. 1C), at residue 106 (identiﬁed by the green square; (A) (where
lysine in the human ephrin-B2 sequence replaces arginine in the mouse) was corrected in a more recent PBD entry 3GXU (as used
in (B). The predicted potential KLK4 cleavage sites in mouse ephrin-B2 and the corresponding sequences in human ephrin-B2 are
indicated by the red arrowheads and are numbered from 1 to 5. The conﬁrmed KLK4 cleavage site in mouse ephrin-B2 and the
corresponding sequence in human ephrin-B2 are boxed in red. The number of the amino acid within each sequence is shown to
the right for each line of the aligned sequences. (B) Models of the mouse ephrin-B2 sequence (PDB 1IKO) and the corrected human
ephrin-B2 (PBD 3GXU) sequences showing the position of the predicted KLK4 cleavage site 1 at arginine 159 (Arg159). The
predicted position of the Arg side chain is shown by the yellow circles. The positions of two other Arg residues in the murine
ephrin-B2 sequence are also indicated. One of these (Arg91) is conserved in human ephrin-B2 but the other is not (Lys106,
indicated by red arrow).
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when the bands were clearly visible.N-terminal sequencing
Protein fragments generated by cleavage reactions were separated
on a 10% SDS-PAGE gel (with a 4% stack) and transferred onto
Immobilon-FL Polyvinylidene ﬂuoride (PVDF) membrane (Milli-
pore, Billerica, Minnesota, USA). The membrane was then stained
with 0.25% Coomassie Blue R-250 in 40% methanol/10% acetic acid
and destained with 5% methanol/7.5% acetic acid. The protein
bands that corresponded with ephrin-B2 cleavage fragments were
excised for N-terminal sequencing at the Australian Proteome
Analysis Facility (Sydney, NSW, Australia).Results
In silico identiﬁcation of the EphB4 ligand, ephrin-B2, as a
potential substrate of KLK4
An in silico approach, enhanced Proteomic Identiﬁcation of
Cleavage Sites (ePICS) [Stansﬁeld, Stephens, Clements, manuscript
in preparation] was used to identify potential KLK4 consensus
cleavage sites in proteins in the UniProt database for which crystal
structures were available. This included the extracellular receptor
binding domain of mouse ephrin-B2 (Fig. 1A). This approach is an
extension to the PICS methodology reported by Schilling et al. [37]
and is designed to identify those potential substrates where the
cleavage sites map to the surface of the protein and would
therefore be accessible to the protease. The KLK4 consensus
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Fig. 3 – KLK4 cleavage of murine ephrin-B2. (A) A ﬁxed amount of murine ephrin-B2-Fc (100 ng; lanes marked withþeB2-Fc) was
incubated with decreasing amounts of active KLK4 from a 1:1 ephrin-B2 to KLK4 molar ratio (100 ng ephrin-B2þ41 ng KLK4) to a
1:1/1000 ephrin-B2 to KLK4 ratio. Fragments were separated by SDS-PAGE and visualised using silver staining. KLK4, full length
eB2-Fc, eB2-Fc fragments and the Fc fragment are indicated by arrows. Molecular weight markers (M) are shown on the left. A
representative example of three independent experiments is shown. (B) Fragment bands (labelled Peptides 1–3) from lane 5 of the
silver-stained gel (indicated by blue box in A) were extracted and subjected to N-terminal sequencing to identify the KLK4 cleavage
sites in the mouse ephrin-B2 protein. (C) The N-terminal sequences are shown and are illustrated diagrammatically. The N-
terminal end of full length ephrin-B2-Fc begins with R27. The primary cleavage site (Peptide 2) occurs after R178 within the
ephrin-B2 extracellular domain (ephrin-B2 ecd; R∇NHGPTR). A second signiﬁcant cleavage site (Peptide 3) was identiﬁed within the
human IgG Fc fragment (R∇SCDKTH). (D) Human ephrin-B2 is cleaved less efﬁciently with KLK4 and is unlikely to be a biological
substrate. Mouse ephrin-B2-Fc (mouse eB2-Fc) and human ephrin-B2-Fc (Human eB2-Fc) were cleaved with KLK4 at molar ratios
of 1 ephrin:1 KLK4, 1 ephrin:1/10 KLK4 and 1 ephrin:1/100 KLK4. Proteins were separated by SDS-PAGE and visualized by silver
staining. Uncleaved ephrin-B2-Fc proteins were used as controls for the full length proteins (indicated by the eB2-Fc arrows).
Cleavage fragments of several sizes are indicated by the bracket arrows (eB2-Fc cleavage fragments). A representative example of
two independent experiments is shown. (E) A heat map showing the KLK4 preferred amino acids in the substrate P and P0
positions. Amino acids are shown in single letter code on the left of the heat map. More intense yellow indicates this amino acid is
more preferred in this position, more blue indicates less preferred. Boxes indicate the amino acids found speciﬁcally in the
validated KLK4 cleavage site in mouse ephrin-B2 (white boxes), amino acids common to this sequence in both human and mouse
ephrin-B2 extracellular domain (red boxes), and found speciﬁcally in human ephrin-B2 (green boxes).
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Fig. 4 – Murine ephrin-B2 is glycosylated and this post-
translational modiﬁcation may regulate KLK4 cleavage.
(A) NetNGlyc 1.0 was used to predict potential N-glycosylation
sites within the extracellular domain sequence (R27–R178) of
ephrin-B2. Two sites were identiﬁed—one at asparagine N11
(site NSSN) and at asparagine N114 (site NGSL). (B) Ephrin-B2-
Fc (eB2-Fc) was treated with PNGase F (PF) or KLK4 (K4) or
both enzymes together. Efﬁcient KLK4 cleavage of ephrin-B2-
Fc in the PNGase F buffer (eB2-FcþK4 in PF buffer) was
conﬁrmed. Human IgG Fc fragment (Fc) þ/ KLK4 was used as
a control. Proteins were separated by SDS-PAGE and visualized
by silver staining. A representative example of two
independent experiments is shown. The positions of the
molecular weight markers (M) are indicated. The boxed region
highlights lower molecular weight bands that correspond to
the N-terminal ends of the ephrin-B2 protein. The red box
identiﬁes the 16.9 kDa de-glycosylated fragment R27–R178. The
white asterisk identiﬁed a new ephrin-B2 fragment only seen
after deglycosylation prior to KLK4 digestion.
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mentally validated cleavage sites in known substrate proteins
including pro-KLK3, pro-KLK11, prostatic acid phosphatase, uro-
kinase receptor, pro-urokinase, pro-meprin, enamelin, amelo-
genin, parathyroid hormone-related peptide (PTHrP) and mem-
bers of the insulin-like growth factor (IGF) and IGF binding
protein (IGFBP) families [38,39]. A high ePICS score (Fig. 1B and
C, red boxes) identiﬁes that part of the protein as a potential
target for KLK4 cleavage. PBD model 1IKO (Figs. 1B and 2B)
corresponds to the crystal structure of murine ephrin-B2 amino
acids 30–207 produced by the yeast Pichia pastoris and analysed
by X-ray diffraction with a resolution of 1.92 À [40]. Structure was
determined for amino acids 30–170 only, because the remaining
37 amino acids form a ﬂexible structure, completely disordered in
the electron density map and for which no co-ordinates could be
determined [40]. Flexible structures may still be accessible to
proteases, however, and so this sequence was included in the
ePICS analysis. Human ephrin-B2 was modelled on the structure
of mouse ephrin-B2 to produce PBD entry 2HLE (Fig. 1C), however
a mistake in the sequence at residue 106 (green square; Fig. 2A)
(where lysine in the human ephrin-B2 sequence replaces arginine
in the mouse) was corrected in a more recent entry 3GXU (as used
in Fig. 2B).
As illustrated in Fig. 1B and C (red boxes), the ePICS approach
identiﬁed both murine and human ephrin-B2 as potential targets
for KLK4 cleavage. Five different potential cleavage sites were
identiﬁed at the same positions in each sequence (Fig. 2A—red
arrows). One site (#1, blue box), identical between murine and
human ephrin-B2 sequences, was identiﬁed in the modelled part
of the mouse and human proteins between Arg (R)159 and Ala (A)
160 of murine ephrin-B2 and this site does indeed map to the
surface of the folded proteins (Fig. 2B—blue boxes). The other four
predicted sites (#2–5) (Fig. 2A) were within the undetermined
ﬂexible sequence from amino acids 171 to 207. Despite the high
level of homology overall between the two ephrin-B2 sequences,
there were three amino acid differences within the P4–P40
sequence at predicted cleavage site 2 (Fig. 2A—red boxed
sequence). Sites #3, 4 and 5 were identical in both sequences.
Biochemical conﬁrmation of ephrin-B2 cleavage by KLK4
To conﬁrm that the in silico approach for the identiﬁcation of KLK4
cleavage sites was successful, we next determined in vitro whether
KLK4 could indeed cleave the extracellular domain of murine
ephrin-B2. The entire extracellular domain of recombinant mouse
ephrin-B2 (NCBI reference sequence NP_034241.2), from Arg 27 to
Ala 227 fused to the Fc region of human IgG1 via a ﬂexible linker
sequence at the C-terminus (eB2-Fc), was incubated with auto-
activated recombinant KLK4. The recombinant murine eB2-Fc
protein migrates at 60–65 kDa in SDS-PAGE under reducing con-
ditions and was visualized by silver staining (Fig. 3A). Progressive
cleavage of murine eB2-Fc was seen as the ratio of KLK4 to eB2-Fc
increased, with complete fragmentation at a 1 EphB4:1 KLK4 molar
ratio (lane 2). Speciﬁc fragments were seen in the sample to which
the lowest amounts of KLK4 (1 EphB4:1/100 and 1: 1/1000 KLK4)
were added, although full-length eB2-Fc was still present (lanes 5
and 6). The major band in all lanes at 37 kDa was shown to be an Fc
fragment (see below).
The three most strongly silver stained bands in lane 5 – peptides
1–3 in Fig. 3B – were excised and the N-terminal amino acidsequence of each was determined (Fig. 3B). As expected, the largest
band with the N-terminus at Arg 27 corresponded to the entire
eB2-Fc parent peptide (Band 1 in Fig. 3B, Fig. 3C). The second largest
band (approx 50 kDa) matched an epitope in the mouse ephrin-B2
extracellular domain sequence that would be produced by cleavage
after Arg 178 (Fig. 3C). This is site 2 (Fig. 2A), which falls within the
ephrin-B2 sequence for which the 3-dimensional structure could
not be determined. The second shorter sequence (approx 37 kDa)
matched a site within the Fc sequence of the recombinant eB2-Fc
protein showing that band 3 contains most of the Fc tag (Fig. 3B and
C). The identities of the other two fragments of approximately 25
and 20 kDa were not determined but are presumed to be fragments
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cleavage events, as they are detected by an N-terminal ephrin-B2
antibody (see below and Fig. 5C). Discrepancies in the predicted
sizes of fragments, as based on amino acid sequence, and the size of
these fragments may be explained by potential post-translational
modiﬁcations. The NetNGlyc 1.0 Server was used to interrogate the
ephrin-B2 Arg 27-Arg 178 sequence for potential N-glycosylation
sites and two were identiﬁed within the extracellular domain, one
at Asn 11 (site NSSN) and one at Asn 114 (site NGSL) (Fig. 4A). To
conﬁrm that the ephrin-B2 recombinant protein we used is
glycosylated, a deglycosylation reaction using PNGase F was per-
formed. A decrease in the molecular weight of the ephrin-B2 band
was visualised using silver staining (Fig. 4B, compare lanes 2 and 3).
We then tested whether de-glycosylated ephrin-B2 can be cleaved
by KLK4 and found that this was the case and interestingly, a new
fragment was identiﬁed suggesting there is a further KLK4 cleavageK
2
K
3
K
4
T F CG
WB: N-term pAb
75 kDa
50 kDa
37 kDa
25 kDa
20 kDa
Silver stain – ephrinB2 
M K
2
K
3
K
4
T F CG
75
50
37
25
Full l
eB2
clea
fragm
Fig. 5 – Murine ephrin-B2 can be cleaved by KLK4 but not closely r
cleaved with various proteases including KLK2 (K2), KLK3/PSA (K3),
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identiﬁed in samples to which KLK4, trypsin, GluC and chymotryp
KLK3 had been added. The positions of the molecular weight mar
independent experiments is shown.site in the extracellular domain of ephrin-B2 that is blocked by
glycosylation (Fig. 4B, lane 5).
To determine whether KLK4 could also cleave the extracellular
domain of human ephrin-B2, a recombinant human ephrin-B2-Fc
protein (NCBI reference sequence NP_004084.1), corresponding to
Lys 26 to Ala 229 also fused to the Fc region of human IgG1 by a 6
amino acid linker at the C-terminus (eB2-Fc), was also incubated
with auto-activated recombinant KLK4. Cleavage of human
ephrin-B2 by KLK4, however, was much less efﬁcient (Fig. 3D,
lanes 5–7) than cleavage of mouse ephrin-B2 (Fig. 3D, lanes 2–4).
Signiﬁcantly reduced cleavage products were seen for human
ephrin-B2 in the 1 ephrin:1/100 KLK4 lane when compared
(Fig. 3D, lane 7 vs 4) with the same ratio using the murine
ephrin-B2. This suggests that human ephrin-B2 is a less likely
biological substrate for KLK4. The primary KLK4 cleavage site in
murine ephrin-B2 is between Arg 178 and Asn 179, preciselyK
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age fragments are indicated, with the primary KLK4-generated
ragment 2 seen in Fig. 3B. A representative example of three
use ephrin-B2 structural domains and the extracellular domain
for Western blot detection of cleaved extracellular domain
shown in (A) were analysed by Western blot analysis using
s of ephrin-B2 as indicated. Ephrin-B2 cleavage fragments were
sin had been added but not in the samples to which KLK2 or
kers are indicated. A representative example of three
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between mouse and human ephrin-B2. Two of the amino acids
that vary between the sequences are at the validated KLK4
cleavage site in the P20 and P30 positions in mouse ephrin-B2
(HG vs KD) and the third is at P2 (A vs T) (Fig. 2A). Comparison of
these sequences using the heat map used to predict the KLK4
consensus cleavage site (Fig. 3E) showed that there were only
subtle differences in the preference for amino acids at these
differing positions, but suggests that a glycine (G) at position P30,
as in mouse ephrin-B2, may be more favourable for KLK4 cleavage
than the corresponding aspartic acid (D) in human ephrin-B2.
These changes are sufﬁcient to reduce KLK4 cleavage and there-
fore further deﬁne the consensus KLK4 cleavage site.
To determine the speciﬁcity of the murine ephrin-B2 KLK4
interaction, several other proteases, including the closely related
kallikreins KLK2 and KLK3/PSA, the less-selective serine proteases
trypsin, chymotrypsin and GluC, and the subtilisin-like proprotein
convertase, Furin, were also incubated with recombinant mouse
eB2-Fc, and fragmentation detected by silver staining (Fig. 5A). As
expected, due to their lower selectivity, major cleavage products
were present in the trypsin, chymotrypsin and GluC samples,
although these were clearly different fragments than the KLK4
fragments (Fig. 5A, lanes T, G, C,). The primary r50 kDa KLK4
cleavage fragment (red box, Fig. 5A) was not seen with the other
proteases. Cleavage fragments were not seen in the sample to
which Furin was added, which was expected as the mature
extracellular domain of ephrin-B2 does not contain an Arg-X-
Arg/Lys-Arg motif recognised by this protease [41]. There were no
signiﬁcant cleavage fragments in the samples to which KLK2 and
KLK3/PSA had been added suggesting that cleavage of murine
ephrin-B2 was a highly KLK4-selective event and not a general
kallikrein cleavage event.
Western blotting using two different mouse ephrin-B2 speciﬁc
antibodies (Fig. 5B) was used to identify ephrin-B2 containing
fragments. Similar fragmentation speciﬁcity as that seen on silver
staining was observed following Western blot analysis, with the
primary fragment again being the r50 kDa protein (red box,
Fig. 5C and D). The N-terminal polyclonal antibody, designed to an
undisclosed sequence of ephrin-B2, recognised several small
fragments (20–25 kDa), as also seen in the silver stain (Figs. 5A
and 3A), in addition to the primary cleaved fragment that also
includes the Fc fragment (Fig. 5C). These smaller fragments are
not detected with the H83 antibody that recognises sequences
between amino acid 168 and 235 (Fig. 5D), conﬁrming that these
are N-terminal ephrin-B2 fragments. This suggests that once the
primary cleavage event has occurred, the released ephrin-B2
N-terminal fragment can be unwound exposing additional KLK4
sites (e.g. site #1 in Fig. 2A) that are subsequently cleaved.Discussion
Bi-directional signalling that is induced by interactions between
Eph receptors expressed on one cell and their ligands, the ephrins,
anchored to the surface of another cell, is critical in mediating
signals important to several fundamental biological processes
[2,42]. Dysregulation of Eph-ephrin interactions, for example
through low ephrin expression, high Eph expression, Eph muta-
tions and/or differential cellular compartmentation, leads to
modulation of the forward and/or reverse signalling pathwaysand disruption of the normal Eph-ephrin functions. This can lead
to several developmental disorders and cancers [2].
Evidence now also strongly suggests that another potential
mechanism for dysregulating Eph-ephrin interactions is the
proteolytic cleavage of either receptor or ligand from the mem-
brane of the expressing cells [1]. Protease-mediated cleavage of
some Ephs or ephrins has been shown to modify cell–cell
adhesion and signalling [24].
The EphB4- ephrin-B2 interaction, in particular, is recognised as
being important in cancer as it determines whether EphB4 may
be tumour promoting or tumour suppressive—in prostate [10],
breast [11,43] and oesophageal cancers [12]. Thus, we hypothe-
sised that proteases secreted by PCa cells or adjacent normal
stromal cells with which they interact, may modulate EphB4-
ephrinB2 interactions by cleaving ephrin-B2 and preventing
activation of EphB4, which would normally result in tumour
suppression. Instead, such cleavage could facilitate tumour cell
migration, invasion and tumour angiogenesis via ligand-
independent mechanisms. Using a bioinformatics screen, we
identiﬁed murine ephrin-B2 as a likely proteolytic target for the
serine protease kallikrein-like peptidase 4 (KLK4). As increased
expression of KLK4 in prostate and other epithelial cancers
correlates with cancer progression [44], and over-expression of
KLK4 in PC3 PCa cells induces epithelial to mesenchymal transi-
tion and increased migration/invasion [45], we hypothesised that
at least part of the tumour promoting role of KLK4 may be
through cleavage of ephrin-B2 and subsequent dysregulation of
EphB4-ephrin-B2 interactions. We tested this prediction using
recombinant murine ephrin-B2-Fc and human KLK4 proteins and
conﬁrmed that a KLK4 cleavage site was present in murine
ephrin-B2 by N-terminal sequencing. However, when similar
cleavage experiments were performed using human ephrin-B2,
cleavage was only detected when a high molar ratio of KLK4:
ephrin-B2 was used and we conclude from this result that human
ephrin-B2 is a less likely/relevant biological substrate for KLK4.
There is signiﬁcant amino acid sequence variance (3/8 residues)
within the identiﬁed P4-P40 cleavage site that is likely the basis
for the differential cleavage efﬁciency.
The implication of this ﬁnding may be profound when con-
sidering mechanisms at play in the human clinical situation and
needs to be considered when interpreting the results of studies
using EphB4 and KLK4 positive human prostate tumours in
murine xenografts. Increased ephrin (reverse) signalling and
increased tumour-promoting angiogenesis has been previously
linked to cleavage of the ectodomain by proteases including
matrix metalloproteinases MMP-8, -9 and -12, and ADAM8,
ADAM10 and ADAM13 [20–22]. Removal of the ectodomain of
ephrin-B2 is followed by release of an intracellular C-terminal
fragment (CTF) by action of Presenilin-1/γ-secretase [19]. The CTF
then regulates intracellular ephrin-B2 signalling pathways invol-
ving c-Src and leads to increased angiogenesis [19]. Further, the
CTF of ephrin-B1, when over-expressed in COS cells can translo-
cate to the nucleus suggesting that, like other intracellular
cleavage fragments of type 1 single-span transmembrane proteins
such as the key cell differentiation molecule Notch [46], this
intracellular fragment could act as a transcriptional regulator [18].
Alternatively, an additional but contrasting impact of cleavage
and release of the ephrin-B2 ectodomain is via its potential
interaction with, and possible activation of, its EphB receptors
(EphB2, EphB4) expressed on PCa cells. In vitro studies have
Fig. 6 – Model of the proposed differential effect of KLK4 cleavage of ephrin-B2 in mouse xenograft versus human prostate cancer
endothelial cells. In a mouse xenograft model (left panels), KLK4 released by human prostate cancer cells can interact with and
cleave ephrin-B2 expressed on host (murine) endothelial cells, thereby triggering reverse signalling mechanisms and stimulating
angiogenesis. Interaction of the cleaved ephrin-B2 ectodomain with the prostate cancer cell EphB4 is dysregulated. In contrast, in
the human clinical situation released KLK4 is unable to efﬁciently cleave host (human) ephrin-B2, cleavage-derived angiogenesis
pathways are inactive and potentially normal ephrin-B2/ephB4 interaction can occur.
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activate the kinase activity of EphB4 in cancer cells and initiate
tumour suppressive effects [10,13]. Non-clustered (monomeric)
soluble ephrin-B2 ectodomain can bind Eph receptors but this
results in different biological responses to those effected by
clustered soluble ephrin-B2-Fc [1,2]. Further studies are required
to examine the structural nature of the KLK4-cleaved ectodomain
–monomeric or clustered – and the potential functional impact of
ephrin-B2 cleavage.Conclusion
Implicitly, these data suggest that ectodomain cleavage of ephrin-B2
may be a signiﬁcant mechanism that regulates the migration and
metastasis of PCa cells in vivo. However, in presenting the ﬁrst
evidence that the key PCa serine protease, KLK4, can speciﬁcally and
efﬁciently cleave the ectodomain of mouse ephrin-B2, KLK4 appears
not to similarly efﬁciently cleave human ephrin-B2. Therefore, one
may see differential effects of KLK4 on regulation of human PCa cells
in mouse xenografts as opposed to tumours in situ in human tissues
(Fig. 6). We suggest that differences in protease action against human
and mouse target proteins should be taken into consideration when
performing xenograft experiments. In the mouse, xenografts of
EphB4 over-expressing human PCa cells, which also over-express
and secrete KLK4, provide a scenario in which the KLK4 may cleave
ephrin-B2 expressed by host mouse endothelial and ﬁbroblast cells.
This can result in increased angiogenesis due to activated ephrin-B2
reverse signalling, prevention of normal interaction with PCa cell
EphB4 and therefore inhibition of ligand-dependent tumour sup-
pressive signalling. These outcomes would lead to alteration of the
behaviour of the PCa cells in vivo and enhanced tumour progression.
In contrast, the same response, at least mediated by KLK4, is not
likely to occur with prostate tumours in man as human KLK4 is less
able to cleave human ephrin-B2. This does not rule out processing of
ephrin-B2 in the human circumstance by other proteases, such as
ADAMs, which may therefore have a similar effect in promoting
angiogenesis, but it does suggest that the known prostate tumour
promoting role of KLK4 in the human is not via ephrin-B2 cleavage.
Nonetheless, these data provide a model for further explorationof possible protease-mediated control mechanisms underlying
the complex tumour-suppressive and tumour-promoting effects of
EphB4-ephrin-B2 signalling.Acknowledgments
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